Feasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer

Korábbi kezelés

• 4. Persistent severe diarrhea, hand-foot ulcers, or severe malnutrition at baseline that precludes tolerance of chemotherapy;
• 7. Regular use of anti-tumor Chinese patent medicines, traditional Chinese herbal decoctions, long-term acupuncture/moxibustion for cancer treatment, or anti-cancer dietary supplements within the 2 weeks prior to enrollment, making washout period unfeasible;
• 8. Receipt of radiation therapy, other chemotherapy drugs, targeted therapy, or immunotherapy within the month prior to enrollment;
• 9. Patients currently undergoing double-agent chemotherapy or immunotherapy;
• 10. Refusal to discontinue other anti-cancer traditional Chinese medicine interventions or inability to truthfully report concomitant medications.

Más betegség

• 2. History of other systemic malignancies or gastrointestinal in situ cancer within the past 5 years;
• 3. Presence of severe underlying organic diseases affecting the heart, liver, kidneys, respiratory system, or hematopoietic system;
• 5. Consciousness disorders or psychiatric conditions preventing independent completion of scale assessments and follow-up;
• 6. Known allergy to any ingredient in Huangqi Yangyuan Formula or capecitabine;

Egyéb

• 1. Pregnant or breastfeeding women;

• 1. Aged 18-80 years.
• 2. Histologically confirmed stage IIIB-IV colorectal adenocarcinoma.
• 3. Eligible for planned or ongoing capecitabine monotherapy.
• 4. Expected survival ≥ 6 months.
• 5. ECOG performance status 0-2.
• 6. Baseline bone marrow, hepatic, and renal function adequate for chemotherapy.
• 7. Able to comply with oral medication, scheduled visits, and quality-of-life assessments.
• 8. Willing to provide written informed consent.